Ethos Technologies Inc (LIFE)
NASDAQFinancialsInsurance - BrokersSnapshot 2026-10-15
NASDAQFinancialsInsurance - BrokersSnapshot 2026-10-15
Research Workspace
Put LIFE beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Improve adjusted EBITDA to $103M-$107M for 2026: Direct metric needs a verified mapping.
View ThesisMiddle-of-the-pack management execution.
View ManagementModerate volatility — typically moves about 3% a day.
View RiskLIFE's claim rests on achieving 2026 revenue guidance, despite weak recent financial performance and a dragging sector. Revenue grew 113% year over year in Q2 FY2026, and adjusted earnings beat consensus. LIFE trades at 28× P/E versus the 12× peer median, near its 24× history. The price is roughly in line with the growth forecast, but the premium must be earned. Margin compression threatens revenue guidance, and our model puts the next-quarter miss probability near 26%. The primary adjusted EBITDA pillar is under pressure, though its metric mapping remains unverified. Peer multiples imply a price about 78% below where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-16. LIFE is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 10 analysts currently covering LIFE (as of Oct 2026).
Based on 6 Wall Street analysts offering 12-month price targets for LIFE in the last 4 months.
Continue this research
Compare LIFE with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| LIFE Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-10-15. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Insurance Brokers — fair value, gap to price, and forward P/E.
Compare the value case
Put LIFE next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Achieve revenue guidance for 2026
Price target increase reflects confidence in revenue growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-16. EPS is implied from price ÷ P/E. Not investment advice.
Current $37.52
The last 12 months of price, then the range of analyst 12-month targets from today’s $37.52.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.

Advances: Achieve revenue guidance for 2026
Growth push aligns with revenue guidance for 2026.

Threatens: Achieve revenue guidance for 2026
Revenue growth is strong, but margin compression is concerning.

Threatens: Address earnings miss
Stock drop indicates potential loss of investor confidence.